Your browser is no longer supported. Please, upgrade your browser.
Settings
RGLS [NASD]
Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own4.30% Shs Outstand47.82M Perf Week-22.81%
Market Cap66.51M Forward P/E- EPS next Y-0.38 Insider Trans- Shs Float36.65M Perf Month-37.36%
Income-15.70M PEG- EPS next Q-0.09 Inst Own48.50% Short Float17.58% Perf Quarter-47.61%
Sales10.00M P/S6.65 EPS this Y58.20% Inst Trans27.27% Short Ratio2.08 Perf Half Y75.11%
Book/sh0.54 P/B1.60 EPS next Y-5.70% ROA-48.50% Target Price1.33 Perf Year38.32%
Cash/sh0.40 P/C2.14 EPS next 5Y39.60% ROE-109.90% 52W Range0.42 - 2.32 Perf YTD-35.96%
Dividend- P/FCF- EPS past 5Y49.00% ROI-46.10% 52W High-62.74% Beta2.33
Dividend %- Quick Ratio3.20 Sales past 5Y-13.60% Gross Margin- 52W Low104.76% ATR0.13
Employees24 Current Ratio3.20 Sales Q/Q27677.80% Oper. Margin- RSI (14)29.59 Volatility9.37% 11.51%
OptionableYes Debt/Eq0.18 EPS Q/Q88.10% Profit Margin- Rel Volume0.31 Prev Close0.92
ShortableYes LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume3.10M Price0.86
Recom3.00 SMA20-32.05% SMA50-39.26% SMA200-14.14% Volume975,904 Change-5.53%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
May-06-21 03:01PM  
May-03-21 09:25AM  
08:00AM  
Apr-15-21 08:07AM  
Apr-07-21 08:07AM  
Mar-10-21 04:03AM  
Mar-09-21 04:07PM  
Mar-05-21 04:07PM  
Mar-04-21 12:30PM  
Feb-10-21 08:07AM  
Jan-27-21 08:07AM  
Jan-05-21 08:07AM  
Dec-09-20 08:54AM  
Dec-08-20 08:07AM  
Dec-02-20 07:00AM  
Dec-01-20 08:35AM  
Nov-29-20 02:33PM  
Nov-05-20 05:25PM  
04:07PM  
Nov-03-20 12:31PM  
Nov-02-20 08:07AM  
Oct-15-20 08:07AM  
Oct-13-20 08:07AM  
Sep-11-20 08:07AM  
Sep-08-20 08:28AM  
Sep-03-20 08:07AM  
Aug-31-20 08:07AM  
Aug-13-20 06:05PM  
04:07PM  
Aug-06-20 12:30PM  
08:07AM  
Aug-03-20 08:07AM  
Jul-29-20 08:07AM  
Jul-22-20 08:07AM  
Jun-12-20 08:01AM  
May-14-20 04:07PM  
May-07-20 12:30PM  
Mar-12-20 04:37PM  
Mar-09-20 12:30PM  
Feb-13-20 04:30PM  
Jan-21-20 07:47AM  
Dec-22-19 07:44PM  
Dec-16-19 08:00AM  
Nov-18-19 08:07AM  
Nov-15-19 01:37PM  
Nov-12-19 05:55PM  
04:05PM  
Nov-07-19 10:30AM  
Oct-16-19 04:15PM  
Sep-20-19 01:30PM  
Sep-12-19 08:00AM  
Sep-03-19 04:10PM  
Aug-29-19 04:10PM  
Aug-08-19 07:20PM  
04:10PM  
Aug-06-19 02:50PM  
Aug-01-19 10:33AM  
Jul-30-19 08:00AM  
Jul-29-19 11:33AM  
Jul-23-19 06:30PM  
Jun-11-19 05:00AM  
May-10-19 05:39AM  
May-09-19 04:05PM  
May-07-19 04:05PM  
May-06-19 09:15AM  
09:00AM  
May-02-19 10:32AM  
Apr-08-19 08:00AM  
Mar-28-19 09:45AM  
Mar-18-19 08:53AM  
08:00AM  
Mar-15-19 06:00PM  
Jan-07-19 08:00AM  
Jan-04-19 04:05PM  
Dec-20-18 09:56AM  
Nov-28-18 07:35AM  
Nov-19-18 08:00AM  
Nov-08-18 06:40PM  
05:38PM  
04:05PM  
Nov-06-18 07:30AM  
Oct-25-18 04:05PM  
Oct-23-18 11:30AM  
08:35AM  
Oct-22-18 04:05PM  
Oct-18-18 04:05PM  
Oct-17-18 07:45AM  
Oct-04-18 08:05AM  
Oct-02-18 04:05PM  
Sep-27-18 04:05PM  
Sep-26-18 04:05PM  
Sep-19-18 02:22PM  
Aug-23-18 12:50PM  
Aug-09-18 06:10PM  
05:05PM  
04:05PM  
Jul-09-18 09:13AM  
Jul-05-18 05:00PM  
07:35AM  
Jul-03-18 12:38PM  
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aker Christopher RaySr. VP & General CounselFeb 16Sale1.728281,42442,614Feb 17 05:23 PM
Hagan Joseph PPresident and CEOFeb 16Sale1.724,1447,128485,756Feb 17 05:23 PM
Sonsini Peter W.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:13 PM
Walker Paul Edward10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:14 PM
SANDELL SCOTT D10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
MAKOWER JOSHUA10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:12 PM
Florence Anthony A. Jr.10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Makhzoumi Mohamad10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:11 PM
Chang Carmen10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:10 PM
Behbahani Ali10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:09 PM
BASKETT FOREST10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:08 PM
Growth Equity Opportunities V,10% OwnerDec 04Buy0.624,398,6022,735,9306,451,056Dec 07 05:06 PM
Aker Christopher RaySr. VP & General CounselNov 16Sale0.5287645625,762Nov 18 04:10 PM
Hagan Joseph PPresident and CEONov 16Sale0.526,0943,176215,994Nov 18 04:09 PM
Aker Christopher RaySr. VP & General CounselAug 14Sale0.6087252826,638Aug 17 08:21 PM
Hagan Joseph PPresident and CEOAug 14Sale0.604,2452,568222,088Aug 17 08:22 PM
Hagan Joseph PPresident and CEOMay 15Sale0.634,4262,774226,333May 18 04:28 PM
Aker Christopher RaySr. VP & General CounselMay 15Sale0.6390957027,510May 18 04:27 PM